| BACHEM N -B- | 354.50 / -3.27% |
| Date/Time | 01/25 / 17:30 |
| Chg. / Chg.(%) | -12.00 / -3.27% |
| Bid | 353.00 / 76 |
| Ask | 377.00 / 300 |
| Open | 368.50 |
| Previous Close | 366.50 |
| High | 368.50 |
| Low | 353.00 |
| Volume [CHF] | 12,704,695.00 |
| Volume [Units] | 35,551 |
| Price fixings | 1128 |
| ISIN | CH0012530207 |
| Security | BANB |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
| Bid Size | Bid | Ask | Ask size |
|---|---|---|---|
| 76 | 353.00 | 377.00 | 300 |
| 10 | 352.50 | 379.50 | 18 |
| 10 | 352.00 | 380.00 | 25 |
| 35 | 351.00 | 385.00 | 400 |
| 50 | 350.50 | 386.00 | 234 |
| 276 | 350.00 | 390.00 | 240 |
| 20 | 345.00 | 394.50 | 18 |
| 45 | 344.00 | 395.00 | 25 |
| 212 | 340.00 | 396.00 | 670 |
| 6 | 333.00 | 396.50 | 12 |
News
- Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
05/14/2020 / 07:00 - GlobeNewswire - Generex Biotechnology Initiates Peptide Manufacturing for Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
05/04/2020 / 14:30 - GlobeNewswire - Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial
04/28/2020 / 15:24 - GlobeNewswire - Vaccine Contract Manufacturing Market, 2030 - Market is Anticipated to Generate Revenues Worth USD 100 Billion by 2025
10/04/2019 / 10:05 - GlobeNewswire - Global Pharmaceutical Contract Manufacturing Market 2018-2025 - Patent Expiration Of Small Molecules Drugs & Advanced Technologies In API And FDF Manufacturing
03/26/2019 / 10:57 - GlobeNewswire
Real-time